Kardin is commonly used to help with stable angina, a chronic condition where recurrent chest discomfort or pressure is a key manifestation. Its use is relevant in clinical settings where additional symptomatic support is needed for patients whose stable angina is difficult to manage with standard treatments. The medication is commonly used across conditions characterized by periods of heightened symptoms, and contributes to easing the overall symptom load.

The medication is applied in addressing symptoms that interfere with daily functioning and is relevant in situations involving recurrent chest discomfort and symptoms related to physical discomfort. In these clinical scenarios, Kardin may assist with managing the frequency of angina episodes and contributes to easing the associated discomfort. It may support the management of symptoms related to physical discomfort, which can assist with maintaining functional stability and physical tolerance.

It is also considered relevant for certain patients with conditions marked by increased physiological stress to support general well-being and ease symptoms related to systemic imbalance. By easing the overall symptom load associated with these chronic conditions, Kardin contributes to improved day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for Symptoms Related to Physical Discomfort

Kardin may be part of symptomatic management for recurrent chest discomfort and effort-related symptoms in adults with stable angina, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Who Can and Cannot Use Kardin?

The population eligibility for Kardin (Trimetazidine) is strictly defined by government regulatory authorities and is determined by age, underlying neurological status, and kidney function. This medicine is only indicated as an add-on therapy for adults (aged 18 years and above) with stable angina pectoris that is not adequately controlled by other standard treatments.

---

Formal Non-Eligibility (Contraindications)

Kardin must not be used by patients who meet the following criteria, as these are formal contraindications:

• Severe Renal Impairment: Patients with severely reduced kidney function, defined as a creatinine clearance below 30 ml/min.
• Movement Disorders: Individuals with a history of Parkinson disease, parkinsonian symptoms (such as tremors or rigidity), or restless leg syndrome.
• Hypersensitivity: Known allergy to the active substance, Trimetazidine, or any other component of the tablet.

---

Restricted and Conditional Use

Population Group	Eligibility Status	Condition/Restriction
Pediatric Population (under 18)	Not Recommended	Safety and efficacy have not been established in this age group.
Moderate Renal Impairment	Conditional Use	Requires a formal dose reduction (CrCl 30–60 ml/min).
Pregnancy/Lactation	Not Recommended	Use is generally avoided during pregnancy and breastfeeding.
Acute Cardiac Events	Exclusion	Not indicated for the initial treatment of unstable angina or myocardial infarction.

Kardin, containing the active substance Trimetazidine, is officially documented as having a highly specific interaction profile that is defined by the absence of formal drug-drug interactions.

Documented Interaction Profile

Official regulatory labels consistently report that no drug interactions have been identified for Trimetazidine with other medicinal products. Studies cited in regulatory sources indicate that the substance is neither an inducer nor an inhibitor of drug hydroxylation, suggesting an absence of common CYP-mediated metabolic interaction patterns. Furthermore, no interactions have been reported during co-administration with beta-blockers, calcium antagonists, or nitrates.

Interaction Type	Regulatory Finding
Drug-Drug Restrictions	None documented. No substances are formally contraindicated for co-administration.
Metabolic/Transporter	None documented to affect clearance or exposure via these mechanisms.
Food/Alcohol/Herbal	No significant effect of food on the bioavailability is documented. No interaction with alcohol or herbal products is specified.

Population-Specific Exposure Notes

The only official interaction-related constraints involve pharmacokinetic alterations tied to reduced renal clearance. Increased exposure to Trimetazidine is expected in two specific populations, as documented in regulatory texts:

• Moderate renal impairment (creatinine clearance 30-60 mL/min).
• Elderly patients over 75 years.

This structure shows that the product's primary interaction constraint is based on physiological function rather than co-administered medicines.

How Kardin Works

Kardin functions by a highly specific mechanism that focuses on modulating activity within specific receptor or enzyme systems. Its activity is centered across three key mechanistic domains to influence core mechanisms underlying its effect profile.

---

Targeted Receptor and Enzyme Modulation

Kardin's action initiates by selectively engaging defined biological targets, such as specific receptors or regulatory enzymes, within the body. This interaction acts as the primary mechanistic focus, enabling Kardin to either block or modulate the target's activity. This initial engagement is necessary for altering signaling dynamics in defined neural or humoral pathways.

---

Modulating Molecular Signaling Cascades

Following the initial binding, Kardin operates within well-characterized molecular cascades. By modifying early molecular steps, the drug acts to modulate signal transduction in contexts involving heightened pathway activation. The mechanism involves targeted pathway interference used to influence the propagation of overactive signals through the system.

---

Adjusting Physiological Pathway Activity

The ultimate mechanism involves adjusting activity within central and/or peripheral pathways. Kardin’s action is used to influence core mechanisms underlying the drug's effect profile, leading to physiological adjustments that shape the drug’s overall effect profile. This action is associated with modulation across key mechanistic domains within the targeted biological system.

The use of Kardin (Trimetazidine) is administered exclusively via the oral route, following specific instructions for dosage, timing, and preparation. The medicine is available as both a Modified-Release (MR) and an Immediate-Release (IR) tablet.

---

Official Dosing and Frequency

Dosage Form	Standard Adult Regimen	Administration Condition
35 mg Modified-Release Tablet	One tablet, twice daily (morning and evening).	Must be taken during meals and swallowed whole.
20 mg Immediate-Release Tablet	One tablet, three times daily.	Must be taken during meals.

---

Procedural Requirements and Adjustments

All forms of the medicine must be taken during meals to align with specific instructions. The Modified-Release tablets must be swallowed whole and are not to be crushed, chewed, or divided. The continued benefit of the treatment must be formally assessed after three months of use, and therapy should be discontinued if no response is observed.

For adults with moderate renal impairment (creatinine clearance 30–60 mL/min), the dose must be reduced. The recommended reduced dose is typically one 35 mg MR tablet once daily (in the morning) or one 20 mg IR tablet twice daily. Use in the pediatric population (under 18 years) is not established. If a dose is missed, it is recommended to resume the regimen normally and not take a double dose to compensate.

Research evidence / Overview of Studies for Kardin

---

Evidence for Symptomatic Management of Stable Angina Pectoris

The main research base for Kardin consists of Randomized Controlled Trials (RCTs), a primary study design used in clinical research, and subsequent systematic reviews that combine the results from these individual studies. This evidence primarily examined the medicine alongside other existing anti-anginal treatments for stable chest discomfort.

Researchers explored outcomes related to physical discomfort and changes in the frequency of angina episodes. Studies monitored patterns where changes in measurements of angina episode frequency and rescue medication use were observed between the group receiving Kardin and the control group over a short-term follow-up duration. The trials focused on providing insight into short-term changes in symptom burden. However, the existing research provides limited insight into long-term outcomes, as follow-up durations were limited in many primary symptomatic trials.

---

Research Examining Cardiac Function in Related Conditions

Research has explored the study of the medicine in related cardiovascular contexts. This evidence base is comprised of primarily smaller-scale clinical trials and meta-analyses. Findings indicate changes measured during the study period related to heart function and functional capacity were observed in certain populations studied. However, the sample sizes were modest in many of these trials, and the evidence quality varies across studies.

---

Study Focus: Long-Term Follow-up and Durability

Clinical trials primarily focus on short-term symptom relief, and the evidence base for Kardin reflects this emphasis. There is limited information for long-term outcomes regarding the medicine's role in influencing major health events, such as reducing the risk of a heart attack or the need for hospitalization over many years. While some studies have observed responses over defined time intervals, certainty remains low for long-term effects.

---

What Research Shows Is Still Uncertain

One primary uncertainty relates to the absence of large, definitive clinical outcome trials specifically designed to determine the medicine's influence on all-cause mortality or hospitalization rates over many years. Additionally, comparative evidence is lacking from large-scale studies that directly test Kardin against other established second-line antianginal agents, which may make it difficult to contextualize its research profile against those alternatives. While many findings describe group patterns, research does not determine whether an individual will respond similarly, and evidence highlights what is known—and what is still uncertain—about its use in routine clinical practice.

Common questions about Kardin (FAQ)

Q: If I miss a dose of Kardin, what is the generally recognized guidance (non-directive)?

If a dose is missed, the official regulatory guidance instructs that you resume your regimen normally with your next scheduled dose. Patients are instructed to not take a double dose to compensate for the missed one.

Q: What is the typical time frame for dosage adjustments for Kardin?

The continued benefit of the treatment, including any potential need for adjustment or discontinuation, is subject to a formal assessment after three months of use. Official guidance states that if no therapeutic response is observed during this time, the treatment should be discontinued.

Q: How long does it usually take to notice an effect from Kardin?

Clinical studies have examined the medicine's effects over defined short-term follow-up durations, typically 2 to 3 months. Within this time frame, studies have observed improvement in exercise capacity and changes in the frequency of symptoms associated with angina.

Q: What is the difference between Kardin and the generic version of the medicine?

Kardin is a brand name for this medicine. It contains the active ingredient Trimetazidine dihydrochloride. The generic version of the medicine refers to this active substance, Trimetazidine.

Q: What is the half-life of Kardin (how long does it stay in the system)?

The elimination half-life of Trimetazidine is documented in official product information to be between 7 and 12 hours. This value reflects the time it takes for half of the medicine to be cleared from the bloodstream. Exposure to the drug is expected to be higher in individuals who have reduced kidney function.

Q: Is Kardin used for a single condition or for multiple problems?

Regulatory documents officially indicate the medicine for use as an add-on therapy for stable angina pectoris (chest discomfort) in adults. It is intended for those whose condition is not adequately controlled by other standard treatments.

Q: What are the serious but less common side effects associated with Kardin?

Officially reported adverse effects classified as Rare (affecting 1 to 10 users in 10,000) include palpitations, tachycardia (a fast heartbeat), and Orthostatic Hypotension. Orthostatic Hypotension is a sudden fall in blood pressure that can occur when standing up.

Q: Is there a known interaction between Kardin and common over-the-counter pain relievers?

Official regulatory labels consistently report that no drug interactions have been identified for Trimetazidine with other medicinal products. This general finding applies to other medicinal products, which may include common over-the-counter medicines.

Q: Is it true that certain foods or supplements can interact negatively with Kardin?

Official documents state that no significant effect of food on the drug's absorption is documented. Furthermore, no interaction with herbal products is specifically noted in regulatory texts.

Q: Does Kardin interact with alcohol, and what does 'unsafe' mean for drinking?

Although no specific interaction with alcohol is documented, the medicine has been associated with side effects like dizziness and drowsiness. Official information indicates these effects may be potentiated (made stronger) by consuming alcohol.

Q: Does Kardin affect the body's electrolyte balance, like potassium or magnesium?

Regulatory documents list adverse reactions by body system. Effects on the body's electrolyte balance, such as potassium or magnesium levels, are not documented as known side effects in the official product information.

Q: Is Kardin ever prescribed for conditions other than heart problems?

Regulatory documents officially indicate the medicine for use as an add-on therapy for stable angina pectoris in adults. Its authorized use is limited to this specific condition that is not adequately controlled by other standard treatments.

Q: Is it safe to drive or operate machinery while taking Kardin?

The medicine may cause side effects like dizziness and drowsiness, which may affect the ability to drive or use machinery. Patients should be aware that this potential effect is documented in the official product information.

Q: Are there any long-term effects of taking Kardin that patients should be aware of?

Officially documented adverse effects may include the onset or worsening of Parkinsonian symptoms, such as tremor or rigidity. These symptoms can appear after prolonged therapy but are usually reversible upon discontinuation of the medicine.

Q: What are the known risks of combining Kardin with certain antibiotics?

Official regulatory labels state that no drug interactions have been identified for Trimetazidine with other medicinal products. This general finding applies to other medicinal products, which may include antibiotics.

Q: Can Kardin be taken by people with diabetes or thyroid conditions?

There are no specific contraindications listed in regulatory documents for patients who also have diabetes or thyroid conditions. The official contraindications relate to severe renal impairment and existing movement disorders.

Q: What is the difference between Kardin and a beta-blocker?

Kardin is classified as a metabolic agent that supports oxygen-efficient energy use in heart cells. It is described as achieving its therapeutic effects without concomitant haemodynamic effects (such as lowering blood pressure or heart rate), unlike medicines such as beta-blockers.

Q: Does Kardin have any known effects on mental clarity or mood?

Officially reported adverse effects include general nervous system issues like dizziness, headache, and sleep disorders (drowsiness or difficulty sleeping). These effects, which are detailed in the official documents, may indirectly influence mental clarity.

Q: Is Kardin available in different forms (e.g., tablet, capsule, liquid)?

The medicine is supplied as two different types of solid dosage forms: an Immediate-Release (IR) tablet and a Modified-Release (MR) tablet.

Official Storage and Disposal Instructions

All storage and disposal must strictly follow the requirements documented in official regulatory labeling to ensure product stability and safety.

Area	Official Regulatory Requirements
Storage Temperature	Store at a temperature not exceeding 30 C (room temperature).
Environmental Protection	The medicine must be protected from light and moisture.
Handling Constraints	Do not refrigerate or freeze the tablets.
Container Rules	Keep Kardin in its original container or packaging and ensure the container is kept tightly closed.
Child Safety	Keep out of the sight and reach of children and pets.
Disposal	Unused or expired product must be disposed of according to local requirements. Do not throw away via household trash or wastewater. Return the medicine to a pharmacy or authorized take-back program.